The influence of plasma lipoprotein subfractions on 3T3-L1 and human preadipocyte differentiation in cell culture.
Stanton LA., van de Venter M., Oelofsen W.
Animal Study, published in Comp Biochem Physiol B Biochem Mol Biol (1998) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Comp Biochem Physiol B Biochem Mol Biol (1998)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 9787810
- DOI
- 10.1016/s0305-0491(98)10037-8
Abstract (original English)
3T3-L1 and human preadipocyte differentiation was significantly (P < 0.001) enhanced by HDL2, LDLII/III and LDLIV. The concentrations of lipoproteins required for maximal differentiation in human preadipocytes were not achieved over the concentration range 50-150 micrograms lipoprotein protein ml-1, whereas maximal differentiation in 3T3-L1 preadipocytes was achieved for all lipoprotein subfractions at approximately 75 micrograms lipoprotein ml-1, a level almost double that required for complete HDL and LDL fractions in 3T3-L1 cells. Despite the enhanced extent of differentiation caused by certain lipoprotein subfractions, the time needed for the conversion process was unaffected. GPDH activity development in both cell types was most pronounced in response to LDLIV, with HDL2 resulting in the lowest activity. In both cell types, the enhancement of differentiation was only evident when the cells were exposed to lipoproteins during the early stage of the program, i.e. before visible formation of lipid droplets.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.